Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jid.2019.10.020 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Uncommon concurrent pulmonary infections: and in an Anti-MDA5 antibody-positive dermatomyositis patient.
Med Mycol Case Rep
March 2025
Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
A 59-year-old female with anti-MDA5 antibody-positive dermatomyositis was treated with prednisolone, tacrolimus, cyclophosphamide, tofacitinib, and plasma exchange. Five months post-treatment, elevated β-D-glucan levels and a pulmonary shadow on CT were noted. was identified, leading to voriconazole initiation.
View Article and Find Full Text PDFAnti-MDA5 Positive Juvenile Dermatomyositis With Macrophage Activation Syndrome: A Case Report.
Cureus
December 2024
Pediatric Medicine, Tawam Hospital, Abu Dhabi, ARE.
Article Synopsis
- There are various inflammatory myopathies, including juvenile dermatomyositis (JDM), which can cause muscle inflammation and weakness, with macrophage activation syndrome (MAS) being a severe complication, though it is not frequently reported.
- A case study of a six-year-old girl with proximal muscle weakness and skin manifestations, leading to a JDM diagnosis, showed elevated lab markers and confirmed muscle involvement through MRI.
- The girl initially improved with steroid therapy, but later tested positive for anti-MDA5 antibodies, indicating a worse prognosis and highlighting the importance of recognizing MAS as a possible complication in JDM patients with these antibodies.
Clinical features and prognosis of anti-MDA5-positive dermatomyositis with coexistent anti-aminoacyl-tRNA synthetase antibodies.
Clin Rheumatol
January 2025
Department of Rheumatology and Immunology, The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China.
Objectives: This study aimed to evaluate the incidence and clinical significance of coexistence of anti-aminoacyl-tRNA synthetase (anti-ARS) antibody in patients with anti-melanoma differentiation-associated gene 5-positive dermatomyositis (anti-MDA5 + DM).
Methods: We assessed a cohort of 246 consecutive patients with anti-MDA5 + DM. Clinical characteristics and survival rates were compared between patients with and without anti-ARS antibodies.
MDA5-positive dermatomyositis without muscle weakness and rash: a case report and literature review.
Front Med (Lausanne)
December 2024
Department of Hematology and Rheumatology, The Second Affiliated Hospital of Xiamen Medical College, Xiamen, China.
Melanoma differentiation-associated gene 5 (MDA5)-positive dermatomyositis (DM) is a rare systemic autoimmune disease associated with a high rate of mortality attributable to rapidly progressive interstitial lung disease. MDA5-positive DM is often complicated by a typical rash and muscle weakness. Herein, we describe a 50-year-old woman who presented with worsening pulmonary symptoms with an absence of typical clinical characteristics.
View Article and Find Full Text PDFTwo case reports of MDA5-type seronegative dermatomyositis.
SAGE Open Med Case Rep
December 2024
Division of Dermatology, Department of Medicine, University of Alberta, Edmonton, AB, Canada.
Dermatomyositis (DM) is an autoimmune idiopathic inflammatory myopathy with characteristic dermatologic manifestations. Myositis-specific autoantibodies (MSAs) delineate DM subtypes and their prognoses. Uncommonly, patients present with distinct clinical features of DM, including photosensitive dermatitis, heliotrope rash, Gottron's papules, and nailfold changes; however, their autoimmune serology is negative for expected MSAs.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!